Can AstraZeneca make good on its promise?
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning! It’s an ASCO-full newsletter today (and be sure to peruse the More Reads for more reads) but there’s so much more this week. We’re previewing tomorrow’s advisory committee on the closely watched MDMA therapy from Lykos Therapeutics, and both Jonathan Wosen and I will be at BIO! Hope to see you there.
Read Original Article: Can AstraZeneca make good on its promise? »
